IPHA vs JAGX

Innate Pharma S.A. vs Jaguar Health, Inc. — Valuation Comparison 2026

IPHA

Biotechnology
Innate Pharma S.A.
Quality
4.8
out of 10
Value Trap
26
LOW
Price
$1.74
Last close
Models
8/13
Active
VS

JAGX

Biotechnology
Jaguar Health, Inc.
Quality
4.2
out of 10
Value Trap
47
WARN
Price
$3.29
Last close
Models
5/13
Active

Model-by-Model Comparison

ModelType IPHA Fair ValueIPHA Upside JAGX Fair ValueJAGX Upside
Bayesian DCF Intrinsic $0.54 -68.7%
First Chicago Scenario $0.48 -75.6% $4.44 +27.9%
ML-RIV Intrinsic $0.66 -90.2%
Dynamic NAV Asset-Based $0.87 -49.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IPHA vs JAGX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IPHA vs JAGX — Which Stock Is More Undervalued?

IPHA scores higher with a 4.8/10 quality rating vs JAGX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Innate Pharma S.A. (IPHA) and Jaguar Health, Inc. (JAGX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IPHA currently trades at $1.74 with a QOC of 4.8/10, while JAGX trades at $3.29 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).